- Purity
- ≥ 99.1%
- Size
- 30 mg vial
- MW
- ~4731 g/mol
- Form
- Lyophilised powder
Metabolic Research
Retatrutide
Triple-agonist GLP-1 / GIP / Glucagon peptide
Retatrutide is a novel investigational triple-agonist peptide targeting GLP-1, GIP and glucagon receptors simultaneously. In published early-phase clinical research it has demonstrated some of the most significant reductions in body weight and metabolic markers of any peptide studied to date, making it the leading subject of contemporary metabolic and obesity research.
Research Benefits
- Studied for pronounced reductions in body weight in trial subjects
- Investigated for improved glycemic and insulin-sensitivity markers
- Explored for reductions in hepatic fat and cardiometabolic risk factors
- Extended half-life supporting weekly dosing in research protocols
Research Context
Studied for its effects on body composition, glycemic regulation, hepatic fat, and cardiometabolic markers in laboratory and clinical research settings.
Compliance Notice
This product is supplied strictly for laboratory research and in-vitro use by qualified professionals. It is not a medicine, is not approved for human or veterinary use, and must not be administered to humans or animals.
Certificate of Analysis
Independently verified purity.
Every batch of Retatrutide is analysed by an independent laboratory using UPLC/MS. The current batch tested at 99.627% and 99.691% purity. View the full test report and verify authenticity below.
- Verification Key (COA)
- 20265154
- Batch
- 2026515
- Reported Purity
- 99.627% / 99.691%